Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Rezolute, Inc./ EFFECT

Notice of Effectiveness · EFFECT

Rezolute, Inc.

RZLTNASDAQEQUITYCurrent

Notice of Effectiveness

Filed Nov 10, 2026Accepted Nov 12, 2026, 12:15 AM ESTFiling CIK 1509261Accession 9999999995-26-003513
View company →Permanent SEC source ↗
Share

Structured filing — EFFECT

primary_doc.xml

Open full document ↗

Notice details

Submission type
EFFECT
Act
33

Effectiveness

Effective date
2026-11-10
Effective time (as filed)
13:00:00
Form
S-3

Registrant 1

Registrant
Rezolute, Inc.
Registrant CIK
0001509261
File number
333-299867

Company context

Rezolute is a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI. For more information, visit www.rezolutebio.com.

Current securities

RZLTNASDAQ · EQUITY · Current

Recent company filings

  1. SCHEDULE 13G - filed by PRUDENTIAL FINANCIAL INC regarding Rezolute, Inc.Nov 13, 2026
  2. Regulation FD Disclosure · Other EventsNov 13, 2026
  3. FWP - filed by Rezolute, Inc. regarding Rezolute, Inc.Nov 13, 2026
  4. 424B5 filingNov 13, 2026
  5. S-3 filingNov 5, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.